Supernus, Inc. has confirmed the payment of a $1 billion special cash dividend to former Indivior Pharmaceuticals stockholders, as part of their merger agreement. This dividend was financed through a new $650 million term loan and existing cash, marking a significant post-merger financial transaction.
Supernus, Inc. has completed a key financial obligation stemming from its merger with Indivior Pharmaceuticals, Inc. by distributing a $1 billion special cash dividend to former Indivior shareholders. This payment was funded partly by a new $650 million term loan from Citibank and partly by existing cash reserves. While the dividend itself is a pre-agreed merger term and thus not a surprise, the financing structure, particularly the new debt, is noteworthy. For Supernus, this signifies the finalization of a major merger-related financial commitment and the integration of the combined entity. For former Indivior shareholders, it represents the final cash component of their previous investment. Short-term, the market may react to the new debt on Supernus's balance sheet, but the long-term focus will be on the performance of the newly combined CNS portfolio. A key risk for traders is how the market assesses Supernus's leverage post-dividend, while an opportunity lies in evaluating the combined entity's future growth prospects.